BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 35532877)

  • 1. FLT3-targeted treatment for acute myeloid leukemia.
    Arai Y; Chi S; Minami Y; Yanada M
    Int J Hematol; 2022 Sep; 116(3):351-363. PubMed ID: 35532877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.
    Song MK; Park BB; Uhm JE
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
    Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
    Wang ES
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia].
    Kawashima N
    Rinsho Ketsueki; 2021; 62(8):954-966. PubMed ID: 34497236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
    Roskoski R
    Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Breakthroughs in FLT3-mutated acute myeloid leukemia treatments].
    Najima Y
    Rinsho Ketsueki; 2023; 64(9):932-941. PubMed ID: 37793868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of FLT3 inhibitors in acute myeloid leukemia.
    Zhao JC; Agarwal S; Ahmad H; Amin K; Bewersdorf JP; Zeidan AM
    Blood Rev; 2022 Mar; 52():100905. PubMed ID: 34774343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of FLT3 in AML: a focus on sorafenib.
    Antar A; Otrock ZK; El-Cheikh J; Kharfan-Dabaja MA; Battipaglia G; Mahfouz R; Mohty M; Bazarbachi A
    Bone Marrow Transplant; 2017 Mar; 52(3):344-351. PubMed ID: 27775694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.
    Fathi AT; Chen YB
    Eur J Haematol; 2017 Apr; 98(4):330-336. PubMed ID: 28000291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
    Daver N; Venugopal S; Ravandi F
    Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
    Hogan FL; Williams V; Knapper S
    Curr Cancer Drug Targets; 2020; 20(7):513-531. PubMed ID: 32418523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
    Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
    Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
    Wang ES
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101103. PubMed ID: 31779982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLT3 inhibitors in acute myeloid leukemia: Current and future.
    Thomas CM; Campbell P
    J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
    Antar AI; Otrock ZK; Jabbour E; Mohty M; Bazarbachi A
    Leukemia; 2020 Mar; 34(3):682-696. PubMed ID: 31919472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which FLT3 Inhibitor for Treatment of AML?
    Senapati J; Kadia TM
    Curr Treat Options Oncol; 2022 Mar; 23(3):359-380. PubMed ID: 35258791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.